特纳综合征女性是否应通过卵母细胞累积来保存生育力?一项多中心研究及系统综述
该回顾性双中心研究纳入14例特纳综合征(TS)患者共24个周期,并结合系统综述共48例患者71个周期数据,发现首周期冷冻成熟卵母细胞数较低(4.0±3.7),卵母细胞累积策略可使部分患者达到10枚以上冷冻卵母细胞;低基线FSH、高AMH及核型中46,XX细胞比例较高与首周期冷冻卵母细胞数较多显著相关,三者组合可预测首周期获得至少6枚冷冻卵母细胞。
要点
- TS患者首周期冷冻成熟卵母细胞数低(4.0±3.7),卵母细胞累积策略被50%(7/14)患者接受。
- 接受累积策略者中57.1%(4/7)和42.9%(3/7)分别达到10枚和15枚冷冻成熟卵母细胞阈值。
- 低基线FSH(<5.9 IU/l)、高AMH(>1.13 ng/ml)及46,XX细胞>1%可预测首周期至少6枚冷冻卵母细胞。
核心结论
- 卵母细胞冷冻保存策略并非适用于所有TS女性,其高基线FSH合并低基线AMH及核型中46,XX细胞比例低显著降低冷冻足够成熟卵母细胞的机会。
- TS患者应受益于相关临床评估、遗传咨询和心理支持,以就生育力保存技术做出知情选择,因为需要多个刺激周期才能保存大量卵母细胞。
研究设计与样本
- 回顾性双中心研究,2011年1月1日至2023年1月1日,纳入14例接受卵巢刺激以保存生育力的TS女性(24个周期)。
- 系统综述当前文献中TS女性卵巢刺激后取卵结局(PROSPERO注册号:CRD42022362352),鉴定出34例额外TS患者、47个取卵结局,来自14篇出版物,合计48例患者、71个周期。
主要发现
- TS患者首周期冷冻成熟卵母细胞数为4.0±3.7。
- 卵母细胞累积策略被50%(7/14)患者接受(2.4±0.5个周期),使每例患者冷冻成熟卵母细胞总数提高至10.9±7.2。
- 拒绝卵母细胞累积策略组中仅1例患者超过10枚成熟冷冻卵母细胞阈值。
- 接受累积策略组中57.1%(4/7)和42.9%(3/7)患者分别达到10枚和15枚成熟冷冻卵母细胞阈值(OR=8(0.6;107.0),P=0.12;OR=11(0.5;282.1),P=0.13)。
- 合并所有已发表数据与本数据(48例患者、71个周期),低基线FSH、高AMH浓度及核型中较高比例46,XX细胞与首周期后较高冷冻卵母细胞数显著相关。
关键数值与推荐
- 低基线FSH浓度(<5.9 IU/l)、高AMH浓度(>1.13 ng/ml)及存在46,XX细胞(>1%)的组合可显著预测首周期获得至少6枚冷冻卵母细胞,为识别有真实机会通过卵母细胞冷冻保存足够生育潜能的患者的客观标准。
临床怎么用
- 作者认为TS患者应受益于相关临床评估、遗传咨询和心理支持,以就生育力保存技术做出知情选择,因为需要多个刺激周期才能保存大量卵母细胞。
局限性
- 结果应谨慎分析,因为TS患者成功活产所需的最佳卵母细胞数仍未知,因文献中其卵母细胞使用报道数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome (TS)? SUMMARY ANSWER: The oocyte cryopreservation strategy is not well adapted for all TS women as their combination of high basal FSH with low basal AMH and low percentage of 46,XX cells in the karyotype significantly reduces the chances of freezing sufficient mature oocytes for fertility preservation. WHAT IS KNOWN ALREADY: An oocyte cryopreservation strategy requiring numerous stimulation cycles is needed to preserve fertility in TS women, to compensate for the low ovarian response, the possible oocyte genetic alterations, the reduced endometrial receptivity, and the increased rate of miscarriage, observed in this specific population. The validation of reliable predictive biomarkers of ovarian response to hormonal stimulation in TS patients is necessary to help practitioners and patients choose the best-personalized fertility preservation strategy. STUDY DESIGN, SIZE, DURATION: A retrospective bicentric study was performed from 1 January 2011 to 1 January 2023. Clinical and biological data from all TS women who have received from ovarian stimulation for fertility preservation were collected. A systematic review of the current literature on oocyte retrieval outcomes after ovarian stimulation in TS women was also performed (PROSPERO registration number: CRD42022362352). PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 14 TS women who had undergone ovarian stimulation for fertility preservation were included, representing the largest cohort of TS patients published to date (n = 14 patients, 24 cycles). The systematic review of the literature identified 34 additional TS patients with 47 oocyte retrieval outcomes after ovarian stimulation in 14 publications (n = 48 patients, n = 71 cycles in total). MAIN RESULTS AND THE ROLE OF CHANCE: The number of cryopreserved mature oocytes on the first cycle for TS patients was low (4.0 ± 3.7). Oocyte accumulation was systematically proposed to increase fertility potential and was accepted by 50% (7/14) of patients (2.4 ± 0.5 cycles), leading to an improved total number of 10.9 ± 7.2 cryopreserved mature oocytes per patient. In the group who refused the oocyte accumulation strategy, only one patient exceeded the threshold of 10 mature cryopreserved oocytes. In contrast, 57.1% (4/7) and 42.9% (3/7) of patients who have underwent the oocyte accumulation strategy reached the threshold of 10 and 15 mature cryopreserved oocytes, respectively (OR = 8 (0.6; 107.0), P = 0.12; OR= 11 (0.5; 282.1), P = 0.13). By analyzing all the data published to date and combining it with our data (n = 48 patients, n = 71 cycles), low basal FSH and high AMH concentrations as well as a higher percentage of 46,XX cells in the karyotype were significantly associated with a higher number of cryopreserved oocytes after the first cycle. Moreover, the combination of low basal FSH concentration (<5.9 IU/l), high AMH concentration (>1.13 ng/ml), and the presence of 46,XX cells (>1%) was significantly predictive of obtaining at least six cryopreserved oocytes in the first cycle, representing objective criteria for identifying patients with real chances of preserving an adequate fertility potential by oocyte cryopreservation. LIMITATIONS, REASONS FOR CAUTION: Our results should be analyzed with caution, as the optimal oocyte number needed for successful live birth in TS patients is still unknown due to the low number of reports their oocyte use in the literature to date. WIDER IMPLICATIONS OF THE FINDINGS: TS patients should benefit from relevant clinical evaluation, genetic counseling and psychological support to make an informed choice regarding their fertility preservation technique, as numerous stimulation cycles would be necessary to preserve a high number of oocytes. STUDY FUNDING/COMPETING INTEREST(S): This research received no external funding. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Brouillet S, Ranisavljevic N, Sonigo C, et al. Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome? A multicenter study and systematic review of the literature. Hum Reprod. 2023. PMID: 37381072. doi:10.1093/humrep/dead135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。